SEC Tracker
Get the app
Person · CIK 1257809

Frank McCormick

Chairman of Oncology at BridgeBio Pharma; director at BridgeBio Oncology Therapeutics

Earlier: Olema Pharmaceuticals, Aduro Biotech and Exelixis

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$33.9M
Noticed on Form 144$25.9M
Bought on Form 4$0
Companies5

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
BridgeBio Pharma BBIOCommon StockDirectly10,579Jun 22, 2026 · Filing · EDGAR
BridgeBio Pharma BBIOCommon StockBy the Francis P. McCormick Rev Trust U/A DTD 1/27/2017756,665Jun 22, 2026 · Filing · EDGAR
BridgeBio Pharma BBIOCommon StockSee Footnote627,689Dec 26, 2023 · Filing · EDGAR
BridgeBio Pharma BBIOStock Option (Right to Buy)
exercise $68.92, expires Jun 21, 2036, into Common Stock
Directly5,277Jun 22, 2026 · Filing · EDGAR
BridgeBio Oncology Therapeutics BBOTStock Option (Right to Buy)
exercise $7.73, expires Jun 15, 2036, into Common Stock
Directly31,675Jun 16, 2026 · Filing · EDGAR
Olema PharmaceuticalsCommon StockDirectly191,113Nov 23, 2020 · Filing · EDGAR
Olema PharmaceuticalsCommon StockSee Footnote84,260Nov 23, 2020 · Filing · EDGAR
Aduro BiotechStock Option (Right to Buy)
exercise $6.60, expires Jun 5, 2028, into Common Stock
Directly20,000Jun 6, 2018 · Filing · EDGAR

Sold and noticed by quarter

Frank McCormick: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$13.3M$0Q1 2021: $0 noticed on Form 144Q1 2021: $0 sold on Form 4Q2 2021: $0 noticed on Form 144Q2 2021: $0 sold on Form 4Q3 2021: $0 noticed on Form 144Q3 2021: $0 sold on Form 4Q4 2021: $0 noticed on Form 144Q4 2021: $0 sold on Form 4Q1 2022: $0 noticed on Form 144Q1 2022: $0 sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $4.2M noticed on Form 144Q4 2023: $4.2M sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $0 sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $4.4M noticed on Form 144Q2 2025: $4.4M sold on Form 4Q3 2025: $3.9M noticed on Form 144Q3 2025: $3.9M sold on Form 4Q4 2025: $13.3M noticed on Form 144Q4 2025: $13.3M sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2025$13.3M$13.3M
Q3 2025$3.9M$3.9M
Q2 2025$4.4M$4.4M
Q4 2023$4.2M$4.2M
Q4 2020$4.3MNot machine-readable
Q4 2019$3.8MNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
BridgeBio Pharma BBIO · Merrill Lynch · 10b5-1 plan adopted Aug 28, 2024 · 3 notices
Oct 29, 2025198,359 · ~$13.2MOct 29, 2025Sold as noticed Sold 198,359 in 5 sales, Oct 29 to Oct 29 · $13.2M Form 4Filing · EDGAR
Oct 27, 20251,641 · ~$107KOct 27, 2025Sold as noticed Sold 1,641 at $65.00 on Oct 27 · $107K Form 4Filing · EDGAR
Jun 24, 2025100,000 · ~$4.4MJun 24, 2025Sold as noticed Sold 100,000 at $44.23 on Jun 24 · $4.4M Form 4Filing · EDGAR
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Sep 5, 202574,000 · ~$3.9MSep 5, 2025Sold as noticed Sold 74,000 at $53.16 on Sep 5 · $3.9M Form 4Filing · EDGAR
BridgeBio Pharma BBIO · Merrill Lynch · 10b5-1 plan adopted Jun 15, 2023 · 1 notice
Dec 26, 2023100,000 · ~$4.2MDec 26, 2023Sold as noticed Sold 100,000 at $42.06 on Dec 26 · $4.2M Form 4Filing · EDGAR
Sales without a matching Form 144 · 13 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 10,069 at $43.57 on Nov 13, 2020 · $439KFiling · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 58,299 at $42.91 on Nov 13, 2020 · $2.5MFiling · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 31,632 at $42.22 on Nov 13, 2020 · $1.3MFiling · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 900 at $36.86 on Dec 30, 2019 · $33K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 16,250 at $35.74 on Dec 30, 2019 · $581K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 100 at $42.93 on Dec 27, 2019 · $4K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 617 at $42.26 on Dec 27, 2019 · $26K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 883 at $41.31 on Dec 27, 2019 · $36K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 16,858 at $40.13 on Dec 27, 2019 · $676K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 13,705 at $39.27 on Dec 27, 2019 · $538K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 3,500 at $38.09 on Dec 27, 2019 · $133K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 21,656 at $36.85 on Dec 27, 2019 · $798K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable BridgeBio Pharma (BBIO): Sold 25,531 at $36.37 on Dec 27, 2019 · $929K (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

BridgeBio Pharma BBIO Chairman of Oncology · filings 2019 to 2026 · sold $33.9M · $25.9M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 22, 2026Grant or award from the company+3,99010,579 directFiling · EDGAR
Jun 22, 2026Grant or award from the company
Stock Option (Right to Buy)
+5,2775,277 directFiling · EDGAR
Oct 29, 2025Sale under a 10b5-1 plan−111,755$65.48$7.3M766,583
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Oct 29, 2025Sale under a 10b5-1 plan−31,116$66.20$2.1M735,467
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Oct 29, 2025Sale under a 10b5-1 plan−3,497$67.52$236K731,970
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Oct 29, 2025Sale under a 10b5-1 plan−8,598$68.50$589K723,372
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Oct 29, 2025Sale under a 10b5-1 plan−43,393$69.24$3M679,979
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Oct 27, 2025Sale under a 10b5-1 plan−1,641$65.00$107K878,338
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Sep 5, 2025Option or RSU exercised or converted+74,000$11.92$882K157,275 directFiling · EDGAR
Sep 5, 2025Open-market or private sale−74,000$53.16$3.9M83,275 directFiling · EDGAR
Sep 5, 2025Option or RSU exercised or converted
Stock Option (Right to Buy)
−74,00084,814 directFiling · EDGAR
Jun 24, 2025Sale under a 10b5-1 plan−100,000$44.23$4.4M879,979
By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Filing · EDGAR
Jun 20, 2025Grant or award from the company+6,58983.28 directFiling · EDGAR
Jun 20, 2025Grant or award from the company
Stock Option (Right to Buy)
+8,4258,425 directFiling · EDGAR
May 8, 2025Gift−3,00076,686 directFiling · EDGAR
May 7, 2025Gift−33,00079,686 directFiling · EDGAR
Dec 26, 2024Gift−7,400112,686 directFiling · EDGAR
Jun 21, 2024Grant or award from the company
Stock Option (Right to Buy)
+26,01426,014 directFiling · EDGAR
Dec 26, 2023Sale under a 10b5-1 plan−100,000$42.06$4.2M627,689
See Footnote
Filing · EDGAR
Feb 21, 2023Grant or award from the company
Stock Option (right to buy)
+158,814158,814 directFiling · EDGAR
Nov 13, 2020Open-market or private sale−31,632$42.22$1.3M1,268,836 directFiling · EDGAR
Nov 13, 2020Open-market or private sale−58,299$42.91$2.5M1,210,537 directFiling · EDGAR
Nov 13, 2020Open-market or private sale−10,069$43.57$439K1,200,468 directFiling · EDGAR
May 19, 2020Grant or award from the company+39,0421,300,568 directFiling · EDGAR
May 19, 2020Grant or award from the company
Stock Option (Right to Buy)
+10,54910,549 directFiling · EDGAR
Dec 30, 2019Sale under a 10b5-1 plan−16,250$35.74$581K1,262,426 directFiling · EDGAR
Dec 30, 2019Sale under a 10b5-1 plan−900$36.86$33K1,261,526 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−25,531$36.37$929K1,335,895 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−21,656$36.85$798K1,314,239 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−3,500$38.09$133K1,310,739 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−13,705$39.27$538K1,297,034 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−16,858$40.13$676K1,280,176 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−883$41.31$36K1,279,293 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−617$42.26$26K1,278,676 directFiling · EDGAR
Dec 27, 2019Sale under a 10b5-1 plan−100$42.93$4K1,278,576 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted+47,165$0.00$4747,165 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted+132,317$0.00$132179,482 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted+66,729$0.00$67246,211 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted+406,723$0.00$407652,934 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted+418,016$0.00$4181,070,950 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted+290,476$0.00$2901,361,426 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted
Common Units
−47,1650 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted
Common Units
−132,3170 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted
Series B Units
−66,7290 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted
Management Incentive Units
−406,7230 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted
Management Incentive Units
−418,0160 directFiling · EDGAR
Jul 1, 2019Option or RSU exercised or converted
Management Incentive Units
−290,4760 directFiling · EDGAR

BridgeBio Oncology Therapeutics BBOT Director · filings 2025 to 2026

DateTransactionSharesPriceValueHeld afterSource
Jun 16, 2026Grant or award from the company
Stock Option (Right to Buy)
+31,67531,675 directFiling · EDGAR
Aug 26, 2025Grant or award from the company
Stock Option (Right to Buy)
+91,07691,076 directFiling · EDGAR

Olema Pharmaceuticals Director · filings 2020 to 2020

DateTransactionSharesPriceValueHeld afterSource
Nov 23, 2020Derivative converted+152,891191,113 directFiling · EDGAR
Nov 23, 2020Derivative converted+66,32684,260
See Footnote
Filing · EDGAR
Nov 23, 2020Derivative converted
Series A-1 Convertible Preferred Stock
−152,8910 directFiling · EDGAR
Nov 23, 2020Derivative converted
Series A Convertible Preferred Stock
−66,3260
See Footnote
Filing · EDGAR
Nov 18, 2020Grant or award from the company
Stock Option (Right to Buy)
+21,52021,520 directFiling · EDGAR
Sep 18, 2020Grant or award from the company
Stock Option (Right to Buy)
+56,96456,964 directFiling · EDGAR

Aduro Biotech Director · filings 2015 to 2018

DateTransactionSharesPriceValueHeld afterSource
Jun 6, 2018Grant or award from the company
Stock Option (Right to Buy)
+20,00020,000 directFiling · EDGAR
Jun 8, 2017Grant or award from the company
Stock Option (Right to Buy)
+13,00013,000 directFiling · EDGAR
Jun 9, 2016Grant or award from the company
Stock Option (Right to Buy)
+13,00013,000 directFiling · EDGAR
Apr 14, 2015Grant or award from the company
Stock Option (right to buy)
+30,00030,000 directFiling · EDGAR

Exelixis Director · filings 2003 to 2013

DateTransactionSharesPriceValueHeld afterSource
Dec 6, 2013Grant or award from the company
Option (right to buy)
+66,07066,070 directFiling · EDGAR
May 23, 2013Grant or award from the company
Option (right to buy)
+30,00030,000 directFiling · EDGAR
May 24, 2012Grant or award from the company
Option (right to buy)
+15,00015,000 directFiling · EDGAR
May 19, 2011Grant or award from the company
Option (right to buy)
+15,00015,000 directFiling · EDGAR
May 19, 2010Grant or award from the company
Option (right to buy)
+15,00015,000 directFiling · EDGAR
May 14, 2009Grant or award from the company
Option (right to buy)
+11,25011,250 directFiling · EDGAR
May 2, 2008Grant or award from the company
Option (right to buy)
+15,00015,000 directFiling · EDGAR
May 2, 2007Grant or award from the company
Option (right to buy)
+10,00010,000 directFiling · EDGAR
May 2, 2006Grant or award from the company
Option (right to buy)
+10,00010,000 directFiling · EDGAR
Apr 23, 2005Grant or award from the company
Option (right to buy)
+10,00010,000 directFiling · EDGAR
Apr 9, 2004Grant or award from the company
Option (right to buy)
+10,00035,000 directFiling · EDGAR
Jul 29, 2003Grant or award from the company
Option (right to buy)
+25,000$8.29$207K25,000 directFiling · EDGAR
All 47 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Jun 24, 2026Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 18, 2026Form 4BridgeBio Oncology Therapeutics BBOTFiling · EDGAR
Oct 31, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
Oct 29, 2025Form 144BridgeBio Pharma BBIOFiling · EDGAR
Oct 29, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
Oct 27, 2025Form 144BridgeBio Pharma BBIOFiling · EDGAR
Sep 8, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
Sep 5, 2025Form 144BridgeBio Pharma BBIOFiling · EDGAR
Aug 28, 2025Form 4BridgeBio Oncology Therapeutics BBOTFiling · EDGAR
Aug 18, 2025Form 3BridgeBio Oncology Therapeutics BBOTFiling · EDGAR
Jun 26, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 24, 2025Form 144BridgeBio Pharma BBIOFiling · EDGAR
Jun 24, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
May 9, 2025Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jan 8, 2025Form 4/ABridgeBio Pharma BBIOFiling · EDGAR
Dec 27, 2024Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 25, 2024Form 4BridgeBio Pharma BBIOFiling · EDGAR
Dec 28, 2023Form 4BridgeBio Pharma BBIOFiling · EDGAR
Dec 26, 2023Form 144BridgeBio Pharma BBIOFiling · EDGAR
Feb 28, 2023Form 3BridgeBio Pharma BBIOFiling · EDGAR
Feb 23, 2023Form 4BridgeBio Pharma BBIOFiling · EDGAR
Nov 23, 2020Form 4Olema PharmaceuticalsFiling · EDGAR
Nov 19, 2020Form 4Olema PharmaceuticalsFiling · EDGAR
Nov 18, 2020Form 3Olema PharmaceuticalsFiling · EDGAR
Nov 17, 2020Form 4BridgeBio Pharma BBIOFiling · EDGAR
May 21, 2020Form 4BridgeBio Pharma BBIOFiling · EDGAR
Dec 31, 2019Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jul 3, 2019Form 4BridgeBio Pharma BBIOFiling · EDGAR
Jun 27, 2019Form 3BridgeBio Pharma BBIOFiling · EDGAR
Jun 8, 2018Form 4Aduro BiotechFiling · EDGAR
Jun 12, 2017Form 4Aduro BiotechFiling · EDGAR
Jun 10, 2016Form 4Aduro BiotechFiling · EDGAR
Jun 26, 2015Form 4Aduro BiotechFiling · EDGAR
Apr 14, 2015Form 3Aduro BiotechFiling · EDGAR
Dec 9, 2013Form 4ExelixisFiling · EDGAR
May 24, 2013Form 4ExelixisFiling · EDGAR
May 25, 2012Form 4ExelixisFiling · EDGAR
May 20, 2011Form 4ExelixisFiling · EDGAR
May 20, 2010Form 4ExelixisFiling · EDGAR
May 14, 2009Form 4ExelixisFiling · EDGAR
May 5, 2008Form 4ExelixisFiling · EDGAR
May 3, 2007Form 4ExelixisFiling · EDGAR
May 3, 2006Form 4ExelixisFiling · EDGAR
Apr 25, 2005Form 4ExelixisFiling · EDGAR
Apr 9, 2004Form 4ExelixisFiling · EDGAR
Aug 5, 2003Form 3ExelixisFiling · EDGAR
Jul 31, 2003Form 4ExelixisFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.